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Immune checkpoint receptors (IC) positively or negatively regulate the activation of the
host immune response, preventing unwanted reactions against self-healthy tissues. In
recent years the term IC has been mainly used for the inhibitory ICs, which are critical to
control Natural Killer (NK) and Cytotoxic CD8+ T cells due to its high cytotoxic potential.
Due to the different nature of the signals that regulate T and NK cell activation, specific
ICs have been described that mainly regulate either NK cell or T cell activity. Thus,
strategies to modulate NK cell activity are raising as promising tools to treat tumors that
do not respond to T cell-based immunotherapies. NK cell activation is mainly regulated
by ICs and receptors from the KIR, NKG2 and NCRs families and the contribution of T
cell-related ICs is less clear. Recently, NK cells have emerged as contributors to the
effect of inhibitors of T cell-related ICs like CTLA4, LAG3 or the PD1/PD-L1 axes in
cancer patients, suggesting that these ICs also regulate the activity of NK cells under
pathological conditions. Strikingly, in contrast to NK cells from cancer patients, the level
of expression of these ICs is low on most subsets of freshly isolated and in vitro activated
NK cells from healthy patients, suggesting that they do not control NK cell tolerance
and thus, do not act as conventional ICs under non-pathological conditions. The low
level of expression of T cell-related ICs in “healthy” NK cells suggest that they should
not be restricted to the detrimental effects of these inhibitory mechanisms in the cancer
microenvironment. After a brief introduction of the regulatory mechanisms that control
NK cell anti-tumoral activity and the conventional ICs controlling NK cell tolerance, we
will critically discuss the potential role of T cell-related ICs in the control of NK cell activity
under both physiological and pathological (cancer) conditions. This discussion will allow
to comprehensively describe the chances and potential limitations of using allogeneic
NK cells isolated from a healthy environment to overcome immune subversion by T
cell-related ICs and to improve the efficacy of IC inhibitors (ICIs) in a safer way.
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INTRODUCTION
Natural Killer (NK) cells are a class of innate lymphocytes
that have evolved to eliminate rapidly infected and tumor
cells. In humans there are two main subsets, phenotypically
and functionally different, classified phenotypically according
to the level of membrane expression of CD56 and CD16 and
functionally according to their cytotoxic potential (1, 2). The
CD56dimCD16pos NK cell subset is eminently cytotoxic and
expresses high levels of perforin and granzyme B. They share
similar immunosurveillance function and killing mechanisms
with the other main cell population responsible for killing
infected or tumor cells, cytotoxic CD8+ T (Tc) cells. However,
mature NK cells can exert their cytotoxic function without
previous activation and independently of the presence of non-
self antigens presented by MHC molecules. Despite the ability of
NK cells to eliminate target cells without previous sensitization,
it is now well-known that previous activation enhances NK
cell activity by regulating the expression of both cytotoxic
mediators and several receptors as explained below (Figure 1)
(3, 4). Moreover, a previous exposition to specific antigens
(haptens), viral infection (CMV) or cytokines (IL12, IL15, and
IL18) generates a type of NK cells known as adaptive NK cells
that possess immunological memory features (5). However, the
mechanisms that regulates the generation of adaptive NK cells
are not clear yet and, specifically, it is not known if the HLA-
self peptide complexes play any role in this process (6). However,
previous results suggest that, at least in mouse models, this is
not the case since mature NK cells are able to proliferate when
transferred into MHC-I deficient recipients (7).
FIGURE 1 | Regulation of Tc and NK cell activity by ICs in physiological conditions. The canonical ICs, involved in tolerance are indicated in bold. See also
Tables 1, 2. Receptors with no clear functions are indicated with?. It is not clear if B7H3 plays an inhibitory or activating role in T cell tolerance; TIM has been shown
to inhibit or activate NK cells.
Since the activity of mature educated NK cells does not
depend on neoantigens presented by MHC, they might be
the perfect candidates to develop therapeutic strategies to
eliminate tumors that are not visible for T cells either because
they have downregulated MHC/HLA-I or because they do
not present “good” HLA-I associated antigens. However, as
it will be discussed below, since the key steps involved in
the regulation of T and NK cells are different, it is very
difficult to extrapolate the wide knowledge acquired on T
cell regulation to NK cells, including the function of some
inhibitory immune checkpoints (ICs) like CTLA-4 and PD1.
Indeed, the development of specific immunotherapy protocols
based on NK cells to treat cancer has been dampened by
the complexity of the mechanisms that regulate NK cell
function and elimination of target cells. Luckily, times are
changing and, at present, in the era of cancer heterogeneity and
immunotherapy, NK cells are emerging as the golden boys to
eliminate non-antigenic tumor cell clones. A perfect duet in the
symphony of destruction, Tc and NK cells destroying immune
“visible” and “invisible” cancer cells to overcome immunogenic
tumor heterogeneity.
However, to fully exploit the potency of this consortium in a
safe way, it is required to understand in more detail the role of
ICs in the regulation of Tc and/or NK cells during physiological
immune responses as well as in the cancer microenvironment. As
indicated in the summary, conceptually IC could be defined as
any molecule involved in the regulation of the immune response,
either in a positive or negative way. However, for reasons of
clarity, in this review the term IC will be used to refer to the
inhibitory ICs, unless the contrary is indicated.
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TABLE 1 | Canonical human NK cell checkpoints.
Receptor CD Effect Other
cell types
Ligand Tolerancea Induced/Constitutive
KIR-L CD158 Inh T, Tγδ, Tm HLA- I Yes C
CD94/NKG2A CD159a Inh T CD8+, Tγδ HLA-E Yes C
ILT2 CD85j Inh T, B, Tm HLA-A, B, C, HLA- G
UL18
? C
KLRG-1 - Inh ILC2, T Cadherins Yesb C
LAIR-1 CD305 Inh T, B, myeloid Collagen Yesb C
NKRP1A CD161 Inh T, NKT, ILC LLT1 ? C
Fc?RIII CD16 Act T, myeloid IgG-Fc Yes C
KIR-S CD158 Act T, Tγδ, Tm HLA-I Yes C
NKp30 CD337 Act ILC2, T, Tγδ c B7H6, BAG6/BAT3 Yes C
NKp44 CD336 Act ILC3, myeloid MLL5
Nidogen-1 HLA-DP
? I
NKp46 CD335 Act - Properdin, HA, HN Yes C
NKp65 - Act - KACL ? C
NKp80 - Act T CD8+, Tγδ AICL ? C





Act T CD8+, Tγδ HLA-E Yes C
2B4 CD244 Act/Inhc T, Tγδ, granulocyte CD48 Yes C
DNAM-1 CD226 Act T, B, granulocyte CD112 (Nectin-2),
CD155 (PVR)
No C
41BB CD137 Act T, myeloid, endothelial,
tumor
CD137L No I
ICOS CD278 Act T ICOS-L
B7RP-1
No I
OX40 CD134 Act T, NKT granulocyte OX40-L
(CD252)
No I
HA, Hemagglutinin; HN, Hemaglutinin-Neuraminidase; LFA, Lymphocyte function-associated antigen 1; MICA/B, Major histocompatibility complex (MHC) class I chain-related protein
A/B; MLL5, Mixed lineage leukemia 5; Tm, Memory T cell; PVR, Poliovirus receptor; ULBP, UL16-binding protein; C, constitutive; I, induced.
aRegulation of human NK cell education and/or tolerance.
bRole in NK cell tolerance is controversial.
c2B4 is an activating receptor in human mature NK cells but an inhibitory receptor in mouse NK cells, human NK cell precursors during NK cell differentiation and in X-linked
lymphoproliferative disease (XLP) patients.
? No reported function on NK cell tolerance.
THE CANONICAL IMMUNE CHECKPOINTS
OF NK CELLS (NK CELL-ICs)
The mechanisms involved in the regulation of NK cell self-
tolerance and immunosurveillance against damaged cells has
been by far much less understood that those regulating Tc cell
activity (8). However, the knowledge accumulated during the
last two decades has allowed to reveal a plethora of receptors
involved in the regulation of NK cell activation and elimination
of tumor cells. These receptors are known as ICs of NK
cells (NK cell-ICs), since they are involved in the regulation
of NK cell tolerance against healthy tissues, while ensuring
an efficient response against damaged cells (Table 1). Thus,
according to the physiological function of ICs, they could be
considered as canonical ICs. Among others, NKG2A, KIRs and
2B4 are considered as canonical NK cell-ICs and have been
proposed to regulate NK cell self-tolerance, also known as NK
cell education (9, 10). It should be noted here that 2B4 can
act either as an inhibitory or activating NK cell receptor (11).
For example, inhibitory functions have been reported in mouse
NK cells (12), human NK cell progenitors (9), and X-linked
lymphoproliferative syndrome patients (13). In mature human
NK cells, 2B4mainly acts as an activating receptor (Figure 1). NK
cell education is also regulated by the activating NK cell receptors
SLAM, NKG2C, NKG2D, and NKp46 (9, 10).
In contrast, the role of other ICs, which are known to regulate
T cell-tolerance and autoimmunity like PD1, CTLA4, or LAG3
(T cell-ICs, Figure 1), in the control of NK cell tolerance is less
clear, and, thus, they should not be considered as canonical ICs
of NK cells, at least under non-pathological healthy conditions.
Indeed, the expression of most of them is very low or absent in
most NK cells from healthy patients (14, 15). A notable exception
is the expression of PD1 that has been identified in a subset of
mature NK cells which share features of adaptive memory-like
NK cells (16). This subset is produced by individuals (around
25% of healthy people) previously exposed to CMV infection
Frontiers in Immunology | www.frontiersin.org 3 January 2020 | Volume 10 | Article 3010
Lanuza et al. Inhibitory Checkpoints in Healthy NK Cells
(17). The role of these non-canonical NK cell-ICs in the function
of healthy NK cells will be discussed in more detail below.
Regulation of NK Cell Activity by NK
Cell-ICs
The net balance between inhibitory and activating signals
transduced by the respective receptors will dictate if a NK cell
kills or respect a target cell (Figure 1) (3, 4).
The inhibitory receptors/ICs mostly interact with HLA-I
molecules and on this way they can sense transformed cells
that have downregulated HLA-I, which makes them invisible for
T cells (Figure 1). The main NK cell-ICs are members of the
KIR (Killer-cell immunoglobulin-like receptor) family, NKG2A
and ILT2 that recognizes HLA-A/B/C, HLA-E/G, and HLA-
G haplotypes, respectively (18–20) (Table 1). As indicated in
Table 1 and Figure 1, other inhibitory receptors modulate NK
cell activity, albeit they have not been considered as ICs, since
its role in NK cell tolerance and education is not clear.
Concerning activating receptors (Table 1), the family of
Natural Cytotoxicity Receptors (NCRs), mainly NKp30, NKp44,
and NKp46 (21) recognize different ligands and NKG2D
recognizes stress ligands of the MIC family (22). Some members
of the KIR family act as activating receptors when binding to
specificHLA-C andHLA-A proteins and toHLA-G (23). NKG2C
is an activating receptor for HLA-E (19, 20). NK cells also express
the activating low affinity IgG receptor (FcγRIII), CD16 that
mediates Antibody Dependent Cellular Cytotoxicity (ADCC)
and the activating receptor DNAM-1 that binds to different
ligands (Table 1). Finally, the C-type lectin receptors NKp65 and
NKp80 also participates in NK cell activation after interacting
with their respective ligands of the CLEC family, KACL, and
AICL (Table 1) (24). NK cells also require adhesion and co-
stimulatory proteins, like LFA-1 or 2B4 to eliminate cancer
cells (25).
The only activating receptor that has not been found in non-
activated NK cells is NKp44 that is rapidly upregulated after in
vitro cytokine-mediated activation (26). Although NKp44 has
been found to be constitutively expressed in a tissue-specific
fashion on type 3 innate lymphoid cells and a subset of DCs
(27), the role of this receptor in tumor immunosurveillance
is not clear since it has not been detected yet in circulating
or tumor infiltrated NK cells in vivo. Thus, in contrast to
most NK cell-ICs and activating receptors, NKp44 has not been
tested yet as a candidate for immunotherapy (28). It should
be noted that an isoform of NKp44 can act as inhibitory
receptor after interacting with the Proliferating Cell Nuclear
Antigen (PCNA) (29). Indeed, it has been recently shown that
an antibody against PCNA enhances the anti-tumoral effect of
NK cells in a mouse model (30), suggesting that NKp44 acts
as an IC in cancer. However, it is not known yet whether this
isoform is a canonical NK cell-IC, regulating NK cell function in
healthy individuals.
It has been recently described that some of these receptors
like NKG2A, NKG2D, or NKp30 are also expressed by some T-
cell subsets (31–33), although their expression in T cells from
healthy individuals seems to be less frequent and they do not
regulate T cell peripheral tolerance. Thus, its action might be
restricted to pathological conditions like infection or cancer.
Indeed, NKG2A has been recently shown to regulate both NK-
and Tc cell-mediated anti-tumoral immunity (34, 35).
Reciprocally, as indicated above, it could be speculated that
the regulatory activity of some ICs involved in the regulation of
T cells like PD1, LAG3, CTLA4, or B7H3 is less pronounced in
NK cells than in T cells (Figure 1). Supporting this hypothesis
several studies have found that, in healthy individuals, CTLA4 is
only expressed at very low levels in the cytosol of NK cells and
PD1 or LAG3 could be restricted to specific memory-like subsets
of individuals previously exposed to CMV infection (16, 36).
Other inhibitory receptors like ILT2, TIGIT, TIM-3, PVRIG,
and TACTILE (CD96) might share regulatory functions in both
NK and T cells, behaving as ICs in both cell types, although in
this case their function in regulating NK cell tolerance is less
clear (37, 38).
The contribution of these non-canonical emerging ICs to
the regulation of healthy NK cell anti-tumoral activity will be
discussed in more detail in section Allogeneic NK Cells Beyond
KIR-Ligand Mismatch-Driven Alloreactivity: The Emerging
Inhibitory NK-ICs.
Modulation of Canonical ICs for Cancer
Immunotherapy
In light of the biological relevance of ICs, regulation of self-
tolerance vs. elimination of infected or transformed cells, it
could be possible to differentiate between Tc cell- and NK cell-
ICs, at least under physiological conditions (Figure 1). Thus,
pharmacological or biological manipulation of NK cell-ICs has
been mainly focused on low immunogenic tumor types that do
not respond to T cell-based immunotherapy and for which the
immunomodulatory role of some Tc cell-ICs like PD1 might be
less pronounced (28). Especially on hematological cancers, where
NK cells occupy the same niches as tumor cells (39).
As indicated above, the increased knowledge about
the receptors regulating NK cell activity and cancer
immunosurveillance is allowing the development of therapeutic
approaches to increase NK cell activity against cancer cells.
These protocols involve mono- and bi-specific antibodies against
inhibitory or activating NK cell-ICs or against membrane tumor
antigens (14, 28) as well as adoptive cell therapy using autologous
or allogeneic NK cells (28).
Monospecific antibodies against membrane tumor antigens
promote ADCC by engaging the activating receptor CD16 onNK
cells. Among all the activating receptors it has been shown CD16
engagement is one of the most potent signals to activate NK cells
and eliminate tumor target cells (40).
Antibodies against inhibitory KIRs were developed and its
efficacy validated in mouse xenograft lymphoma models (41,
42). Subsequently they have entered clinical phase in acute
myeloid leukemia, lymphoma, and some solid tumors. Pending
of finishing the clinical trials, it seems that the anti-tumoral
activity of these antibodies as monotherapy seems to be very
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low. However, the combination with chemotherapy or anti-PD1
antibodies might be more promising (43, 44).
Other antibodies that have been developed include anti-
NKG2A (35) or bi- and tri-specific antibodies engaging NKp46
and/or CD16 and a tumor antigen (45, 46).
Only anti-NKG2A is currently being tested in clinical trials
as monotherapy or in combination with anti-EGFR or anti-
PD1 antibodies. Although the trial is not finished yet the
results combining anti-NKG2A and anti-EGFR seem to be
promising (35).
Albeit most clinical trials testing the antibodies against NK
cell-ICs are still ongoing, the preliminary data indicate that they
are not as efficient as the inhibitors of T cell-ICs, PD1, and
CTLA4, neither against hematological nor against solid cancer
(39). Regarding hematological cancer, this is likely due to that
engaging a single IC is not enough to overcome the unregulated
balance of signals received by NK cells on cancer patients.
This is not easy to overcome since simultaneous engagement
of several NK-ICs might lead to break down self-tolerance and
induce toxicity. Among the potential consequences of targeting
NK cell-ICs, it should be taken into account the implications
of the findings by Carlsten et al. showing that inhibition of
KIR2D by IPH2101 antibody impacts NK cell education (47).
The authors showed a rapid decline in the function of NK
cells from myeloma patients treated with IPH2101, which was
related to the reduction of KIR2D expression on NK cell surface
through monocyte trogocytosis. This treatment would affect the
generation of educated NK cells with anti-tumoral activity due
to the absence of interaction between KIR2D and its HLA-ligand
(48). Thus, it might have a negative impact on other treatments
designed to enhance NK cell activity by regulating ICs.
In the context of solid tumors, in addition to those problems,
the lack of infiltration of NK cells and/or the immunosuppressive
components of the tumor microenvironment might also
contribute to the low efficacy of antibodies against NK cell-
ICs (49).
ADOPTIVE ALLOGENIC NK CELL
THERAPY: KIR-KIR LIGAND MISMATCH
AND NK CELL ALLOREACTIVITY
An ingenious way to overcome the limitations of antibodies
against NK cell-ICs is the use of allogeneic NK cells: NK
cells isolated from healthy haploidentical donors, which are
transferred to patients un-manipulated or after in vitro activation
and expansion. The question that allogeneic NK cells could
efficiently kill tumor cells was addressed by Velardi et al.,
soon after discovery of the HLA-I inhibitory ligands of the
KIR family. This finding indicated that NK cells are able to
sense and response against missing-self or missing-HLA-I (50),
due the loss of inhibitory signals transduced by inhibitory
KIRs (51). Thus, it was found that NK cells generated in the
host after haploidentical bone marrow transplantation presented
alloreactivity against recipient leukemic cells (52), a process
known as KIR-ligand mismatch. The clinical benefit of this
alloreactivity was subsequently confirmed in acute leukemia
patients undergoing allogenic bone marrow transplantation.
Specifically, those patients that received a transplant from an
haploidential donor and, thus, presented NK cell alloreactivity,
prevented leukemia relapse (53). This finding was further
confirmed by Miller’s group (54).
Subsequently, different protocols to activate and expand
allogenic NK cells from healthy haploidentical donors were
developed and infusion of purified NK cells was tested in
leukemia, lymphoma, and myeloma patients as well in solid
tumors with different results (55, 56). In general, these clinical
trials confirm a benefit of KIR-ligand mismatch in acute myeloid
leukemia patients, yet there are number of factors affecting
the effectivity of this protocol which have not been completely
clarified. Among them, it is noteworthy to mention the
selection of donors expressing specific KIR-ligand mismatched
combination and the functional expression of KIRs on the
membrane of NK cells. In addition, it is becoming evident
the importance of selecting an adequate conditioning protocol,
not only to prepare the recipient of the transplant, but also
during the preparations of NK cells to be infused in the patients.
For example, development of protocols that remove specific
cell populations that inhibit NK cell activity like T regulatory
cells (55, 57–59).




Biological Significance of T Cell-Related
ICs: the Emerging NK Cell-ICs
Despite the unsolved questions in the clinical application of
adoptive NK cell therapy, allogeneic NK cells might present
several advantages over therapeutic manipulation of host NK
cells. These advantages go beyond alloreactivity due to missing
HLA-I inhibitory ligands. Specially, it should be stressed that
allogeneic NK cells are selected from a healthy host and are
not under the negative influx of cancer manipulation of host
immunity. Thus, it is tempting to speculate that its action might
not be restricted by ICs employed by cancer cells to overcome
host Tc and NK cell anti-tumoral activity (28).
ICs were discovered in T cells by its ability to regulate
T cell tolerance against self-antigens. Thus, both ICs and co-
stimulatory signals have been shown to be involved in the
regulation of T cell tolerance and prevention of autoimmunity
(Figure 1) (15, 60). Subsequently, it was hypothesized that cancer
cells might take advantage of the regulatory function of ICs to
overcome T cell-immunosurveillance and, thus, pharmacological
manipulation of ICs could be used as an effective cancer
immunotherapy. The best example of this evolution is CTLA-
4 and PD1 ICs. Both regulate T cell tolerance, preventing self-
damage (61–64), and its inhibition by specific antibodies can
reverse T cell inactivation (65) and is effective against specific
cancer types (66, 67).
In contrast to NK cells, the regulation of T cell activity
is restricted by their ability to differentiate self from non-
self antigens and, thus, control of tolerance by inhibitory and
co-stimulatory signals should be different in T and NK cells
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(Figure 1) (15, 60–64). In this context, meanwhile NK cells
mainly counterbalance the activating signals by the presence of
KIRs and other inhibitory ligands recognizing HLA-I (9, 10), T
cells require other inhibitory signals to prevent TCR signaling by
HLA-I-associated self-antigens and/or co-stimulation. Here the
presence of specific T cell-ICs would contribute to self-tolerance,
avoiding autoimmune reactions.
Expression and Function of Emerging NK
Cell-ICs in Cancer and Healthy Individuals
As indicated above this picture might be different under
pathological conditions like cancer, and in those circumstances,
some ICs traditionally associated to T cell function might
promote NK cell immune-evasion by cancer cells (Table 2). Thus,
although NK cells might be important players that contribute
to the anti-tumor activity of IC inhibitors (ICIs) like antibodies
against CTLA-4, LAG3, and the PD1/PD-L1 axes in cancer
patients (68), this should not overestimate the function of some
T cell-ICs in healthy NK cells. Indeed, most of Tc-ICs are
not expressed by NK cells from healthy individuals even after
activation and the level of expression of those that have been
found is much lower than in T cells. These findings, key to
develop efficient protocols and to exploit all the potential of
adoptive allogeneic NK cell therapy, have passed unnoticed in
the NK cell field. Indeed, most studies analyzing the expression
of Tc-ICs in healthy NK cells are restricted to the use of healthy
NK cell controls when analyzing expression of ICs in NK cells
from cancer patients.
Notably, a few studies have analyzed the expression of the
main Tc-ICs, PD1, CTLA-4, TIM-3, LAG3, TIGIT, and VISTA
in freshly isolated and in vitro activated/expanded NK cells in
humans. From these studies it has been consistently reported that
both TIM-3 and TIGIT are expressed by naïve as well as activated
NK cells (69–72). Notably, TIM-3 and TIGIT has been found
to regulate NK cell tolerance in vivo suggesting that they might
work as a canonical IC in NK cells (15). Indeed, TIM3 regulates
NK cell-tolerance during pregnancy (73) and TIGIT regulates
liver regeneration (74). In contrast, it has not been reported yet if
other Tc cell-ICs, like VISTA, PD1, CTLA4, B7-H3/H4, or LAG3,
contribute to NK cell tolerance and would act as canonical ICs of
NK cells (Figure 1).
VISTA has not been found in healthy human NK cells even
after activation (75) and the expression of CTLA4 in human NK
cells is not clear. It was found CTLA-4 in activated mouse NK
cells (76) and later on another group reported that human NK
cells expressed intracellular CTLA4 (77). However, the relevance
of this finding is not clear since it was previously shown that
humanNK cells do not express CTLA4 and are not co-stimulated
by the CD28/CTLA4 pathway (78). In agreement with the later
study, we have not found CTLA4 in the membrane of cytokine-
activated human NK cells (Lanuza et al., in preparation).
Regarding other i ICs like B7-H3 and B7-H4, only B7-H3
has been found in activated healthy NK cells (79). However,
although B7-H3 seems to be a negative regulator of both Tc
and NK cell activity in mouse cancer models (80), in contrast
to T cells, it does not seem to be involved in the regulation
of NK cell tolerance (79). Finally, inhibitory LAG3 is expressed
by activated NK cells (81) although it has not been found to
contribute to the regulation of NK cell tolerance (15) and/or NK
cell cytotoxic activity (82). A recent work found out that LAG3
was expressed at very low levels in activated NK cells, but its
expression was substantially increased in the adaptive NK cell
subset chronically exposed to NKG2C ligands like antibodies
or CMV-infected cells (36). Importantly, these cells presented
low activity against tumor cells, suggesting that memory-like NK
TABLE 2 | Emerging human NK cell checkpoints.
Receptor CD Effect Other
cell types
Ligand Tolerancea Induced/Constitutive
B7H3 CD276 Inh T, B, Treg, myeloid,
non-immune cells, tumor
- No I
TIGIT CD226 Inh T, NKT PVR (CD155)
Nectin-2/-3 (CD112, 113)
Yes C
TIM3 CD366 Act/ Inh T, NKT, myeloid Gal-9, HMGB1, PS,
CEACAM1
Yes C
LAG3 CD223 Inh T, NKT, Treg, B HLA-II, L-sectin, FGL1 No I
PD1 CD279 Inh ILC-2, T, B, NKT, myeloid PD-L1, PD-L2 No I
CTLA4 CD152 Inh T, Treg B7-1, B7-2 No Unknown
PVRIG CD112R Inh T PVRL2
Nectin-2 (CD112)
? C
TACTILE CD96 Act/Inh? T, NKT PVR (CD155)
Nectin-1 (CD111)
?b C
CEACAM1, Carcinoembryonic antigen-related cell adhesion molecule 1; FGL1, Fibrinogen-like protein 1; ILC, Innate Lymphoid cell; Gal-9, Galectin 9; HMGB1, High mobility group box
1; PS, Phosphatidylserine; Treg, regulatory T cell; C: constitutive, I: induced.
aRegulation of human NK cell education and/or tolerance.
bThe role of CD96 in NK cell education/tolerance is not clear. It has been found that NK cells from mice deficient for CD96 are hyperactivated after LPS challenge. Both inhibitory and
activating functions have been reported for CD96.
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cells from healthy donors previously infected with CMV, might
become exhausted in case of CMV reactivation or after exposure
to a new CMV infection in patients transferred with this NK cell
subset. Notably, all experiments were performed in the presence
of IL15 suggesting that chronically activation of adaptive NK
cells in the presence of NKG2C ligands might require IL15 for
induction of PD1 and LAG3 expression. However, the specific
role of IL15 in this process is not completely clarified yet since
the analyses of chronical activation with other cytokines like IL21
was not performed.
This issue is of special interest in light of the different
protocols to expand allogenic NK cells that commonly rely on
IL15 presence and the recent findings suggesting that continuous
stimulation by IL15 exhausts NK cells (83). Since this study did
not analyse the expression of PD1 and LAG3 on NK cells, it will
be important to find out whether long term expansion of NK cells
in the presence of IL15 could render NK cell populations whose
anti-tumoral activity might be restricted by PD1 and/or LAG3.
Different Function of the PD1/PD-L1
Inhibitory Axes in the Regulation of NK
Cells in Cancer vs. Healthy Individuals
It seems that only TIM3 and TIGIT are clearly expressed and act
as conventional ICs in NK cells (15, 69–72) and, thus, they might
contribute to the regulation of NK cell anti-tumoral activity
during adoptive allogeneic NK cell therapy. But, what about the
golden boy of ICs in cancer immunotherapy, the PD1/PD-L1
inhibitory axes?
Recently, it has been shown that NK cells contribute to the
efficacy of antibodies against the PD1/PD-L1 axes in vivo (84).
This finding confirms that PD1 is not only inhibiting T cells in
the cancer microenvironment but, in addition, it prevents NK
cell anti-tumoral activity. Studies in humans have also suggested
such a function since NK cells from cancer patients express
increased levels of PD1, which correlates with a lower anti-
tumoral activity (85–87).
However, and in contrast to NK cells isolated from cancer
patients, the role of PD1/PD-L1 inhibitory axes in the anti-
tumoral activity of NK cells from healthy donors is unclear.
Indeed, its contribution to the anti-tumoral activity of allogeneic
NK cells has not been clarified yet. In a recent study we have
analyzed the role of PD /L1 inhibitory axes in the anti-tumoral
activity of NK cells against colorectal cancer cells (88). Using
colorectal cell lines expressing different levels of PDL1 expression
we found that activated allogeneic NK cells can kill colorectal
cancer cells irrespectively of PDL1 expression. This finding
indicates that allogeneic healthy NK cells can overcome the
PD1/PD-L1 inhibitory axes. However, since we did not analyse
the effect of PD1/PD-L1 inhibitors, it is still possible that blocking
of the PD1/PD-L1 axes increases the anti-tumoral activity of
healthy allogeneic NK cells. If true, activated allogeneic NK
cells should express PD1, an issue that still requires further
clarification (89).
It should be noted here that in contrast to T cells, PD1
seems not to be involved in the regulation of NK cell tolerance,
indicating that like in the case of CTLA4, LAG3, VISTA, or
B7-H3/4, PD1 is not a conventional IC in NK cells. This is
not surprising since the level of expression of PD1 in the
membrane of naïve and activated NK cells from most healthy
patients is generally very low in comparison with activated
T cells or with NK cells from cancer patients (85–87, 90).
In line with these findings, it has been recently found that
a pool of intracellular PD1 is expressed at low level by both
naïve and activated NK cells from healthy patients. Notably, the
expression of this pool of cytosolic PD1 did not increase after
in vitro cytokine activation and neither naïve nor activated NK
cells expressed membrane PD1 (91). As indicated previously,
a notable exception was recently reported by Pesce et al. who
found that PD1 could be expressed at high levels in a subset
of NK cells corresponding to fully mature cells, detectable in
peripheral blood from around 25% healthy individuals who
were serologically positive for cytomegalovirus (CMV) (16). This
subset corresponded to CD56dim NK cells characterized by the
absence of NKG2A and a high expression of CD57 and KIR,
indicating an adaptive memory-like NK cell phenotype. This
finding was confirmed later on by Merino et al., who reported
a significant increase of PD1 (together with LAG3 as mentioned
above) in the adaptive NK cell subset chronically activated by the
NKG2C receptor, involved in CMV recognition (36).
Although it is not clear yet the significance of this finding,
it merits special attention due to the special characteristics of
adaptive memory-like NK cells. It has been found that in the
context of viral infections adaptive NK cells specifically respond
against the specific virus for which they were originally activated
(5, 6). Thus, somehow it could be said that they are restricted
by specific antigens/signals, although this restriction does seem
to involve HLA-mediated antigen presentation (7). Thus, it
could be speculated that similarly to T cells, the expression of
PD1 and LAG3 in adaptive NK cells might be related to the
regulation of antigen specificity, albeit this hypothesis will require
experimental validation. In the context of tumor development,
the role of antigen specificity in the generation and response of
adaptive NK cells is not known.
Anyway, these findings suggest that like in the case of
LAG3, PD1 expression could be upregulated in NK cells
that have responded to CMV infection and thus, healthy NK
cells from these individuals might be partially regulated by
the PD1/PD-L1 inhibitory axes. A question that should be
taken into account when designing protocols for adoptive NK
cell therapy.
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
The emergence of ICIs like antibodies against the PD1/PD-
L1 axes and CTLA4, or more recently against TIM3, LAG3,
TIGIT, or PVRIG, has supposed a great advance in the treatment
of very aggressive cancers like melanoma and lung carcinoma
(92). These treatments mainly rely on the generation of robust
cytotoxic T (Tc) cell responses against mutations/neoantigens
present in cancer cells. Indeed, cancer has learnt to use the
main T cell-related ICs, naturally evolved to control T cell
activity and avoid autoimmunity, to overcome T cell-mediated
recognition and destruction. However, several tumor types
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present low immunogenicity and do not respond to these
therapies, remaining incurable. Even immunogenic cancers that
initially respond to ICIs, frequently relapse due to the selection
of poorly immunogenic cell clones and/or the apparition of
alternative resistance mechanisms (92, 93). The combination
of different ICIs like PD1/PD-L1 and CTLA4 inhibitors to
overcome these limitations often increases toxicity and treatment
has to be discontinued (92).
As an alternative, the use of NK cells isolated from
haploidentical healthy patients and activated in vitro, allogeneic
NK cells, presents several advantages thatmight help to overcome
the limitations of ICI immunotherapy and to treat patients that
do not respond to ICIs. First, alloreactivity due to KIR-HLA-
I mismatch overcome the main NK cell-ICs, KIRs, and thus
the inhibitory signals by HLA-I expressing tumor cells (52–
54). Second, NK cell tolerance and NK cell-mediated cancer
and infection immunosurveillance are mainly regulated by ICs
different from T cell-related ICs (3, 4, 8) (Figure 1). Thus, NK
cells developed in a healthy environment and activated in vitro
should not be affected by cancer immune evasion based on ICs
of T cells. Canonical inhibitory NK cell-ICs include the KIR
family, NKG2A and ILT2 and among other ICs, only TIM3
and TIGIT have been clearly found to be involved in NK cell
function in healthy individuals (3, 4, 8). Thus, the most potent
ICs found in cancer, CTLA4, LAG3, and the PD1/PD-L1 axes
should not affect the cytotoxic anti-tumoral activity of allogeneic
NK cells. Finally, in contrast to Tc cells, which strictly depends on
the activating signals transduced by the TCR after recognizing
antigens presented by HLA-I, NK cells present a vast array of
receptors that transduce activating signals like activating KIRs,
NCRs of NKG2D/C. Thus, reduction of the inhibitory signals in
the tumor microenvironment employing healthy allogeneic NK
cells that express few T cell-ICs should unmask cancer cells to be
efficiently eliminated by transferred activated NK cells.
However, in order to develop efficient protocols based on
allogeneic NK cells to treat solid and hematological tumors and
generate activated NK cells resistant to ICs, some limitations and
open questions needs to be solved. Among them, we propose
some key questions that, from our point of view, are important
and deserve further experimental validation.
1. It will be important to find out if healthy in vitro activated
allogeneic NK cells are induced to express other T cell-ICs
like PD1, CTLA4, VISTA or LAG3 by cytokines present in
the tumor microenvironment. On this regard it was recently
found that PD1was induced by TGF β in T cells (94, 95). It will
be interesting to analyse if a similar effect is found in healthy
activated NK cells.
2. It will be interesting to find out if specific cytokines or
other stimulus are able to regulate IC expression on NK cells
activated/expanded in vitro. In this regard IL15 was recently
found to exhaust NK cells in long term in vitro cultures,
although the expression of ICs like PD1 or LAG3 was not
analyzed (83). Thus, in order to predict its efficacy on a
personalized way, it should be required to analyse the profile
of T cell-IC expression on in vitro expanded NK cells used
for adoptive cell transfer. Depending on the results specific
protocols for NK cell activation and expansion might be
developed to minimize the expression of ICs on NK cells
without affecting the expansion rate and cytotoxic potential.
3. Since it has been found increased PD1 and LAG3 expression
in adaptive NK cells from CMV positive healthy individuals,
it would be interesting to analyse if other T cell-ICs are also
upregulated in these individuals. This finding also suggests
that selection of CMV negative NK cell donors might help to
generate PD1/LAG3 insensitive NK cells.
4. Combination of antibodies against tumor antigens or against
soluble ligands that inhibits activating NK cell receptors with
allogeneic NK cells should augment the activating signals on
allogeneic NK cells and help to treat cancers that express high
levels of ligands for emerging inhibitory NK-ICs like TIM3
or TIGIT.
5. As indicated, it has been found that low levels of CTLA4
and PD1 are expressed in activated human healthy NK cell
intracellularly. Thus, it will be important to find out the
stimulus that might mobilize PD1 and/or CTLA4 to the cell
membrane and if this low level of expression is enough to
inhibit NK cell-mediated elimination of cancer cells in the
presence of the respective inhibitory ligands. This will be
important to predict if intracellular PD1 will be expressed
on the cell membrane of NK cells once they reach the
tumor microenvironment.
6. It will be important to clarify if the contribution of host NK
cells to immunotherapy with ICIs is due to a direct effect of
ICI to NK cell activation or to a synergic effect between NK
cells and Tc cells released from the IC breaks. On this way
more effective protocols combining allogeneic NK cells and
ICIs could be developed.
7. It will be important to find out the role of specific NK cell-
ICs in tolerance regulation. On this way genetic manipulation
of ICs in NK cells or combination of allogeneic NK cells with
ICIs could be rationally developed to increase the efficacy of
adoptive allogeneic NK cell transfer in a safe way.
Pending of validate experimentally all these hypotheses and
in light of the available experimental evidences, it could be
concluded that the regulation of the anti-tumoral activity of
most subsets of allogeneic activated NK cells by T cell-ICs like
CTLA4, PD1, VISTA, LAG3, or B7H3/4 is low. This might be
an advantage to use adoptive allogeneic NK cell therapy to treat
cancer types that despite presenting high immunogenicity and/or
high levels of ICs do not respond to ICIs. Thus, efforts should be
focused in solving other questions that might affect the efficacy
of allogeneic NK cell therapy like migration and infiltration
into solid tumors or the presence of other immunosuppressive
factors in the tumor microenvironment like immunosuppressive
cytokines or metabolic negative regulators.
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